ImmunityBio (IBRX) Cash from Operations Growth (3y) (2017 - 2026)

ImmunityBio (IBRX) Cash from Operations Growth (3y) (2017 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -5.07%
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 33.08%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 16.64%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -7.60%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 ImmunityBio 7.60 Bn 7.22 Bn 43.97 Mn 3.65%

Historic Data

Download Data
DateValue
Mar 31, 2026 3.65%
Dec 31, 2025 8.13%
Sep 30, 2025 5.11%
Jun 30, 2025 4.37%
Mar 31, 2025 -4.66%
Dec 31, 2024 -5.93%
Sep 30, 2024 -10.74%
Jun 30, 2024 -12.97%
Mar 31, 2024 -20.95%
Dec 31, 2023 -26.02%
Sep 30, 2023 -33.19%
Jun 30, 2023 -20.12%
Mar 31, 2023 -39.42%
Dec 31, 2022 4.94%
Sep 30, 2022 -69.43%
Jun 30, 2022 -75.69%
Mar 31, 2022 -78.94%
Dec 31, 2021 -72.19%
Sep 30, 2021 -60.55%
Jun 30, 2021 -62.34%